title: Inhibitory effects of salmon calcitonin on the tail-biting and scratching behavior induced by substance P and three excitatory amino acids.
abstract: We have examined the effects of salmon calcitonin (SCT), injected into the cerebral ventricle (i.c.v.), on the tail-biting and scratching behavior induced by the intrathecal injection of different types of nociceptive agents, i.e., substance P, N-methyl-D-aspartate (NMDA), kainate (KA), and quisqualate (Quis). Tail-biting and scratching behavior induced by the 4 substances was significantly inhibited by SCT (i.c.v.) in the same manner: the dose-response curves were U-shaped, and the most effective dose was 0.1 IU/mouse in all cases. SCT did not, however, completely inhibit tail-biting and scratching behavior. At its most effective dose, the percent inhibition of substance P-, NMDA-, KA- and Quis-induced behavior were 77.9%, 40.2%, 49.4%, and 52.9%, respectively. These results suggest that SCT has the inhibitory effects of substance P- and glutamate receptor agonists-induced nociceptive response in vivo.
authors.affiliation: Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Yamada
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Iyo
authors.forename: S
authors.initials: S
authors.lastname: Fukui
authors.forename: T
authors.initials: T
authors.lastname: Nabeshima
mesh_terms: D000344:Afferent Pathways / Q000503:physiopathology; D000818:Animals; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000008:administration & dosage / Q000633:toxicity*; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D007608:Kainic Acid / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity; D008297:Male; D051379:Mice; D016202:N-Methylaspartate / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D010147:Pain Measurement; D016318:Quisqualic Acid / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity; D017470:Receptors, Glutamate / Q000187:drug effects*; D018040:Receptors, Neurokinin-1 / Q000187:drug effects*; D013116:Spinal Cord / Q000503:physiopathology; D013373:Substance P / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity*; D013623:Tail
chemical_list: D018690:Excitatory Amino Acid Agonists; D017470:Receptors, Glutamate; D018040:Receptors, Neurokinin-1; D013373:Substance P; D016202:N-Methylaspartate; C028815:salmon calcitonin; D016318:Quisqualic Acid; D002116:Calcitonin; D007608:Kainic Acid